Invited Review

Journal of Neuroimmune Pharmacology

, Volume 4, Issue 2, pp 213-217

First online:

HIV Regulation of Amyloid Beta Production

  • Lynn PulliamAffiliated withVeterans Affair Medical Center, San Francisco, University of California Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The use of antiretroviral therapy for HIV infection has extended the survival of individuals living with HIV. However, the effects of chronic HIV infection and aging are introducing another facet of HIV complications. HIV therapy can calm the immune system and lower viral replication to undetectable but the virus is still present. In the brain, amyloid beta (Aβ) increases during normal aging but Aβ accumulation appears to accelerate in HIV infection. HIV Tat protein inhibits the major Aβ-degrading enzyme neprilysin with the cysteine-rich domain of Tat being essential for this inhibition. In this minireview, we also include new data that the β chemokine, CCL2/MCP-1, associated with HIV migration to the brain, also causes an increase in Aβ. These findings may explain the continued cognitive dysfunction found in HIV-infected individuals controlled on antiviral therapy.


HIV Tat CCL2 MCP-1 amyloid beta brain